Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
ENTA > SEC Filings for ENTA > Form 8-K on 3-Sep-2013All Recent SEC Filings

Show all filings for ENANTA PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro



Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement.

The National Institute of Allergy and Infectious Diseases, or NIAID, has exercised its first two options pursuant to its September 30, 2011 agreement with Enanta. Under these options, NIAID has agreed to provide an additional $9.2 million in funding to Enanta for preclinical and early clinical development of Enanta's Bicyclolide antibiotic, EDP-788, effectively extending the term of the agreement to February 2015.

Enanta has created Bicyclolides with a focus on developing an intravenous and oral treatment for hospital-acquired and community-acquired infections of MRSA (methicillin-resistant Staphylococus aureus). NIAID is funding the development of EDP-788 as a medical, biodefense countermeasure against multiple bacteria such as anthrax, plague and tularemia. NIAID's exercise of these two options will fund additional preclinical work and Phase 1 clinical research with EDP-788.

  Add ENTA to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for ENTA - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now

Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.